NCT01361126 - A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

July 31, 2012

Conditions

Hemophilia B

Interventions

BIOLOGICAL

Recombinant Coagulation Factor IX Albumin Fusion Protein

Study subjects will receive a single dose of 25IU/kg of rIX\_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.

Trial Locations (2)

Unknown

Study Site, Sofia

Study Site, Tel Aviv